Integrum AB (publ)

Stockholm Stock Exchange INTEG-B.ST

Integrum AB (publ) Net Cash Used Provided By Financing Activities for the year ending April 30, 2024: USD -58.69 K

Integrum AB (publ) Net Cash Used Provided By Financing Activities is USD -58.69 K for the year ending April 30, 2024, a -119.65% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Integrum AB (publ) Net Cash Used Provided By Financing Activities for the year ending April 30, 2023 was USD 298.74 K, a -97.49% change year over year.
Integrum AB (publ) Net Cash Used Provided By Financing Activities for the year ending April 30, 2022 was USD 11.89 M, a 4,797.67% change year over year.
Integrum AB (publ) Net Cash Used Provided By Financing Activities for the year ending April 30, 2021 was USD 242.72 K, a -88.95% change year over year.
Integrum AB (publ) Net Cash Used Provided By Financing Activities for the year ending April 30, 2020 was USD 2.20 M, a -5.67% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

Stockholm Stock Exchange: INTEG-B.ST

Integrum AB (publ)

CEO	Mr. Scott D. Flora
IPO Date	May 15, 2017
Location	Sweden
Headquarters	Krokslätts Fabriker 50
Employees	36
Sector	Technology
Industries 3D Printing Biotechnology Composite Materials Medical Instruments Robotics

Description

Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides Osseointegrated Prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoiding bone fractures from accidental loads. The company also provides Neuromotus, a technology that is used for therapy to reduce phantom limb pain after an amputation. It sells its implant systems to hospitals, clinics, and orthopedists worldwide. The company was founded in 1962 and is headquartered in Mölndal, Sweden.

Key trends

Past 5 years